Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Using simulated infectious disease outbreaks to guide the design of individually randomized vaccine trials

View ORCID ProfileZachary J. Madewell, View ORCID ProfileAna Pastore Y Piontti, View ORCID ProfileQian Zhang, Nathan Burton, Yang Yang, View ORCID ProfileIra M. Longini, View ORCID ProfileM. Elizabeth Halloran, View ORCID ProfileAlessandro Vespignani, View ORCID ProfileNatalie E. Dean
doi: https://doi.org/10.1101/2021.01.29.21250703
Zachary J. Madewell
aDepartment of Biostatistics, University of Florida, Gainesville, FL, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Zachary J. Madewell
  • For correspondence: zmadewell@ufl.edu
Ana Pastore Y Piontti
bLaboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University, Boston, MA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ana Pastore Y Piontti
Qian Zhang
bLaboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University, Boston, MA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Qian Zhang
Nathan Burton
cInstitute for Child Health Policy, University of Florida College of Medicine, Gainesville, FL, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yang Yang
aDepartment of Biostatistics, University of Florida, Gainesville, FL, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ira M. Longini
aDepartment of Biostatistics, University of Florida, Gainesville, FL, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ira M. Longini
M. Elizabeth Halloran
dBiostatistics, Bioinformatics, and Epidemiology Program, Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
eDepartment of Biostatistics, University of Washington, Seattle, WA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M. Elizabeth Halloran
Alessandro Vespignani
bLaboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University, Boston, MA, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alessandro Vespignani
Natalie E. Dean
aDepartment of Biostatistics, University of Florida, Gainesville, FL, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Natalie E. Dean
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background/Aims Novel strategies are needed to make vaccine efficacy trials more robust given the uncertain epidemiology of outbreaks. Spatially resolved mathematical and statistical models can help investigators identify sites at highest risk of future transmission and prioritize these for inclusion in trials. Models can also characterize the uncertainty in whether transmission will occur at a site, and how nearby or connected sites may have correlated outcomes. A structure is needed for how trials can use models to address key design questions, including how to prioritize sites, the optimal number of sites, and how to allocate participants across sites.

Methods We illustrate the added value of models using the motivating example of Zika vaccine trial planning during the 2015-2017 Zika epidemic. We used a stochastic, spatially resolved, agent-based transmission model (GLEAM) to generate 1,142 epidemics and site-level incidence at 100 high-risk sites in the Americas. We considered several strategies for prioritizing sites (average site-level incidence of infection across epidemics, median incidence, probability of exceeding 1% incidence), selecting the number of sites, and allocating sample size across sites (equal enrollment, proportional to average incidence, proportional to rank). To evaluate each design, we stochastically simulated trials in each hypothetical epidemic by drawing observed cases from site-level incidence data.

Results When constraining the overall trial sample size, the optimal number of sites represents a balance between prioritizing highest-risk sites and having enough sites to reduce the chance of observing too few endpoints. The optimal number of sites remained roughly constant despite varying the targeted number of events, although it is necessary to increase the total sample size to achieve the desired power. Though different ranking strategies returned different site orders, they performed similarly with respect to trial power. Instead of enrolling participants equally from each site, investigators can allocate participants proportional to projected incidence, though this did not provide an advantage in our example because the top sites had a roughly similar risk profile. Sites from the same geographic region may have similar outcomes, so optimal combinations of sites may be those that are more geographically dispersed, even when these are not the highest ranked sites.

Conclusions Mathematical and statistical models may assist in the design of successful vaccination trials by capturing uncertainty and correlation in future transmission. Although many factors affect site selection, such as logistical feasibility, models can help investigators optimize site selection and the number and size of participating sites.

Competing Interest Statement

APyP, QZ and AV report grants from Metabiota Inc, outside the submitted work.

Funding Statement

This work was supported by the National Institutes of Health R01-AI139761.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Not required.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding: This work was supported by the National Institutes of Health R01-AI139761.

Data Availability

The datasets analyzed during the current study are available from the corresponding author (zmadewell{at}ufl.edu) on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted February 01, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Using simulated infectious disease outbreaks to guide the design of individually randomized vaccine trials
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Using simulated infectious disease outbreaks to guide the design of individually randomized vaccine trials
Zachary J. Madewell, Ana Pastore Y Piontti, Qian Zhang, Nathan Burton, Yang Yang, Ira M. Longini, M. Elizabeth Halloran, Alessandro Vespignani, Natalie E. Dean
medRxiv 2021.01.29.21250703; doi: https://doi.org/10.1101/2021.01.29.21250703
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Using simulated infectious disease outbreaks to guide the design of individually randomized vaccine trials
Zachary J. Madewell, Ana Pastore Y Piontti, Qian Zhang, Nathan Burton, Yang Yang, Ira M. Longini, M. Elizabeth Halloran, Alessandro Vespignani, Natalie E. Dean
medRxiv 2021.01.29.21250703; doi: https://doi.org/10.1101/2021.01.29.21250703

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (453)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (158)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5270)
  • Forensic Medicine (3)
  • Gastroenterology (196)
  • Genetic and Genomic Medicine (759)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (700)
  • Health Policy (361)
  • Health Systems and Quality Improvement (224)
  • Hematology (99)
  • HIV/AIDS (164)
  • Infectious Diseases (except HIV/AIDS) (5890)
  • Intensive Care and Critical Care Medicine (363)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (767)
  • Nursing (43)
  • Nutrition (131)
  • Obstetrics and Gynecology (144)
  • Occupational and Environmental Health (234)
  • Oncology (480)
  • Ophthalmology (152)
  • Orthopedics (39)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (98)
  • Psychiatry and Clinical Psychology (865)
  • Public and Global Health (2023)
  • Radiology and Imaging (349)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)